Loading
RO
Rize Oncology Inc. Stock: price and insider trades · Canada
Rize Oncology Inc.: what insiders have been doing
This page follows insider dealings at Rize Oncology Inc. as filed with SEDI. From 26 October 2025 to 26 October 2026, the disclosure feed for Rize Oncology Inc. logged 2 filings by 2 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 2,733 companies) published 14 filings over the same period, against 2 filings here. Our records for Rize Oncology Inc. go back to 2025, with 13 purchases and no sales on the open market in total.
No insider has bought Rize Oncology Inc. shares on the open market in the past twelve months.
These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Insider Decl.
16
Thresholds
n/a
Buy Volume
€23,143
13 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleWilliam James Garner11 buys
Andre Pereira Fraga Figueiredo2 buys
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 4 November 2025
Declarations16 total
3,000,000 shares@ CA$0.10100.0% of flowCommon SharesTSXSEDI:4599564
2,000,000 shares@ CA$0.10100.0% of flowCommon SharesTSXSEDI:4599562
500 shares@ CA$0.070.0% of flowCommon SharesTSXSEDI:4516326
Canonical exit: 21 Aug 2025 (T+90)
5,000 shares@ CA$0.160.3% of flowCommon SharesTSXSEDI:4516321
Canonical exit: 21 Aug 2025 (T+90)
35,000 shares@ CA$0.14242.5% of flowCommon SharesTSXSEDI:4516325
Canonical exit: 19 Aug 2025 (T+90)
5,000 shares@ CA$0.160.3% of flowCommon SharesTSXSEDI:4515176
Canonical exit: 19 Aug 2025 (T+90)
20,000 shares@ CA$0.07530.5% of flowCommon SharesTSXSEDI:4458546
Canonical exit: 25 May 2025 (T+90)
13,000 shares@ CA$0.07130.3% of flowCommon SharesTSXSEDI:4456639
Canonical exit: 22 May 2025 (T+90)
200,000 shares@ CA$0.09466.1% of flowCommon SharesTSXSEDI:4445030
Canonical exit: 1 May 2025 (T+90)
10,000 shares@ CA$0.09530.3% of flowCommon SharesTSXSEDI:4444218
Canonical exit: 30 Apr 2025 (T+90)
13,000 shares@ CA$0.09510.4% of flowCommon SharesTSXSEDI:4443923
Canonical exit: 29 Apr 2025 (T+90)
25,000 shares@ CA$0.09540.8% of flowCommon SharesTSXSEDI:4443161
Canonical exit: 27 Apr 2025 (T+90)
7,000 shares@ CA$0.08710.2% of flowCommon SharesTSXSEDI:4442594
Canonical exit: 24 Apr 2025 (T+90)
10,000 shares@ CA$0.09180.3% of flowCommon SharesTSXSEDI:4440390
Canonical exit: 21 Apr 2025 (T+90)
10,000 shares@ CA$0.100.3% of flowCommon SharesTSXSEDI:4439980
Canonical exit: 17 Apr 2025 (T+90)
26,376,891 sharesCommon SharesTSXSEDI:4435390
16 of 16 declarations
About Rize Oncology Inc.
Rize Oncology Inc. is a company focused on developing innovative therapies for cancer treatment. It is listed on the XTSE market.
